DDInter1956 DDInter905
A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.
Zalcitabine {u} (Compound) resembles {v} (Compound) Emtricitabine
Emtricitabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Zalcitabine {u} (Compound) resembles {v} (Compound) Emtricitabine
Emtricitabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Cabozantinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Zalcitabine {u} (Compound) resembles {v} (Compound) Gemcitabine
Gemcitabine {u} (Compound) resembles {v} (Compound) Cytarabine
Cytarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Zalcitabine {u} (Compound) resembles {v} (Compound) Cytarabine
Cytarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cannabidiol
Cannabidiol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Zalcitabine {u} (Compound) resembles {v} (Compound) Emtricitabine
Emtricitabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Escherichia coli
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Zalcitabine {u} (Compound) resembles {v} (Compound) Decitabine
Decitabine {u} (Compound) resembles {v} (Compound) Pentostatin
Pentostatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Zalcitabine {u} (Compound) binds {v} (Gene) DCK
DCK {u} (Gene) is bound by {v} (Compound) Clofarabine
Clofarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Zalcitabine {u} (Compound) resembles {v} (Compound) Emtricitabine
Emtricitabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eribulin
Eribulin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Zalcitabine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Clozapine
Clozapine {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Zalcitabine {u} (Compound) binds {v} (Gene) DCK
DCK {u} (Gene) is downregulated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Zalcitabine (Compound) resembles Emtricitabine (Compound) and Emtricitabine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Zalcitabine (Compound) resembles Emtricitabine (Compound) and Emtricitabine may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Zalcitabine (Compound) resembles Gemcitabine (Compound) and Gemcitabine (Compound) resembles Cytarabine (Compound) and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Zalcitabine (Compound) resembles Cytarabine (Compound) and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Zalcitabine (Compound) resembles Emtricitabine (Compound) and Emtricitabine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Zalcitabine (Compound) resembles Decitabine (Compound) and Decitabine (Compound) resembles Pentostatin (Compound) and Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Zalcitabine (Compound) binds DCK (Gene) and DCK (Gene) is bound by Clofarabine (Compound) and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Zalcitabine (Compound) resembles Emtricitabine (Compound) and Emtricitabine may cause a minor interaction that can limit clinical effects when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Zalcitabine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Clozapine (Compound) and Clozapine may lead to a major life threatening interaction when taken with Idelalisib
Zalcitabine (Compound) binds DCK (Gene) and DCK (Gene) is downregulated by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib